Nayzilam Spray
Product Images NDC 50474-500

9 FDA label images from Ucb, Inc. · Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 9 technical images submitted to the FDA as part of the official labeling for Nayzilam (NDC 50474-500). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Ucb, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

Product Images & Figures Index

FDA Label Image

Chemical Structure (Nayzilam 01)

Chemical Structure (Nayzilam 01)
Chemical structure of midazolam, the active ingredient in Nayzilam nasal spray 5 mg/.1mL by UCB, Inc. The diagram shows the molecular framework with rings containing nitrogen atoms, chlorine, and fluorine substituents.*
FDA Label Image

Figure 1 (Nayzilam 02)

Figure 1 (Nayzilam 02)
A Kaplan-Meier survival curve showing the probability of no seizures over 24 hours after administration of the first double-blinded study dose. The graph compares Nayzilam nasal spray with placebo, with Nayzilam represented by a solid blue line and placebo by a dashed black line. Censored data points are marked for both groups.*
FDA Label Image

Figure (Nayzilam 03)

Figure (Nayzilam 03)
An instructional line drawing illustrating components of a nasal spray device labeled as nozzle, finger grips, and plunger. The device is shown from a frontal perspective highlighting these parts for usage guidance.*
FDA Label Image

Figure 1 (Nayzilam 04)

Figure 1 (Nayzilam 04)
An instructional illustration showing hands holding a Nayzilam (midazolam) nasal spray device. The image indicates a "Peel Here" area on the packaging, suggesting how to open or access the product inside.*
FDA Label Image

Figure 2 (Nayzilam 05)

Figure 2 (Nayzilam 05)
An instructional diagram labeled Figure 2 showing a hand holding a nasal spray device with a finger positioned to activate the spray, likely demonstrating how to use the Nayzilam nasal spray (midazolam).*
FDA Label Image

Figure 3 (Nayzilam 06)

Figure 3 (Nayzilam 06)
An instructional illustration showing a person administering Nayzilam (midazolam) nasal spray. The individual is depicted holding the spray device close to one nostril with the head tilted slightly back and eyes closed, demonstrating the proper nasal spray administration technique.*
FDA Label Image

Figure 4 (Nayzilam 07)

Figure 4 (Nayzilam 07)
An instructional line drawing labeled Figure 4 showing a person holding a nasal spray device up to their nose, with an arrow indicating the direction of use. The illustration demonstrates how to position and spray the nasal spray into the nostril.*
FDA Label Image

Figure (Nayzilam 08)

Figure (Nayzilam 08)
FDA Label Image

Principal Display Panel (5 mg Vial Blister Pack Carton)

Principal Display Panel (5 mg Vial Blister Pack Carton)
Packaging label for Nayzilam (midazolam) nasal spray 5 mg, a human prescription drug. The label indicates nasal spray format with 2 nasal spray units, each unit delivering 1 dose. The labeler is UCB, Inc. The label includes usage and storage instructions, barcodes, and a DataMatrix code. The product is manufactured in Italy and marked for nasal use only.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.